Revenue Growth of 20%, Positive Operating Income, and Increased Dairy RNG ProductionRevenues of $62.7 million, an increase of $10.5 million or 20% over the second quarter of 2025, with growth across California Ethanol and Dairy RNG segments and $8.6 million of Section 45Z tax credits Operating income improved by $16.4 million compared to the second quarter of 2025 Net loss of $9.4 million improved by $14.0 million compared to the second quarter of 2025 Adjusted EBITDA of $9.7 million improved by $15.5 million compared to the second quarter of 2025 Aemetis Biogas RNG sales volume grew 38% to 146,900 MMBtu, compared with 106,400 MMBtu in the second quarter of 2025 Ten digester cleanup skids have been received, and two biogas dairy digesters are expected to be commissioned in the third quarter of 2026CUPERTINO, Calif., Aug. 06, 2026...

Obtained FDA clearance to proceed with registrational study (TEMPO-1) of CRB-701 in 2L oropharyngeal cancer and expect to initiate enrollment in September 2026 Concluded last patient last visit in CANYON-1 Phase 1b study (n=240) of CRB-913 in obesity and on track to report data in September 2026 Appointed new Chief Medical Officer, Chief Business Officer, and Board Member to strengthen senior leadership and guide the Company through registrational studies and commercialization readinessNORWOOD, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage company focused on developing new therapies in oncology and obesity, today provided a corporate update and reported financial results for the 2026 second quarter ended June 30, 2026.  “We’ve...

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the second quarter 2026. “Our team has continued to execute on our key strategic priorities to advance our pipeline this year,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “We strengthened our financial position through non-dilutive capital, including the $25M upfront payment related to the exclusive Greater China license for pevifoscorvir sodium. In addition, our partner Amoytop has advanced our potential best-in-class ASO for chronic HBV infection,...

Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) progressing towards closing Completed enrollment of 42 planned subjects in the Phase 1 AVALON trial evaluating VTP-1000 in patients with celiac disease; topline data from multiple ascending dose (“MAD”) expected in the fourth quarter of 2026GERMANTOWN, Md., Aug. 06, 2026 (GLOBE NEWSWIRE) — Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today announced its financial results for the quarter ended June 30, 2026, and provided an overview of the Company’s corporate developments. Barinthus Bio is an immunology and inflammation (“I&I”) company focused on developing therapies that promote immune tolerance with curative potential. “During the second quarter, our primary focus remained advancing the proposed combination...

Generated second quarter 2026 revenue of $64.8 million with record high Commercial IoT subscriber activations. Continued progress on regulatory approval process in connection with the previously announced Merger Agreement with Amazon, with expiration of the waiting period under the HSR Act in July 2026. Continued execution of next-generation satellite constellation initiatives with launch of first set of replacement satellites rescheduled for later this month and further development of third-generation satellites.COVINGTON, La., Aug. 06, 2026 (GLOBE NEWSWIRE) — Globalstar, Inc. (Nasdaq: GSAT) (“Globalstar” or the “Company”), a next-generation telecommunications infrastructure and technology provider, today announced its financial results for the second quarter ended June 30, 2026. Capitalized terms not defined herein have...

— IND and CTA clearances in the United States and New Zealand establish a global Phase 1/2 program for PM577a in Wilson disease; study startup activities underway, with initial clinical data in 2027 — — Favorable arbitration resolution with Beam Therapeutics affirms Prime Medicine’s rights to PM647 in Alpha-1 Antitrypsin Deficiency; IND and/or CTA submission expected in 3Q 2026, with initial clinical data in 2027 — — FDA grants Regenerative Medicine Advanced Therapy designation to PM359; continued regulatory engagement with the FDA toward a BLA submission for PM359 in 1H 2027 — — Cash, cash equivalents, investments, and restricted cash of $108.8 million as of June 30, 2026, providing cash runway into 2027 — CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) — Prime Medicine, Inc. (Nasdaq:...

One-year data demonstrated sustained benefit of once-weekly canvuparatide as a potential PTH replacement therapy in chronic hypoparathyroidism; Phase 3 pivotal trial now recruiting Initial Phase 1 data for MBX 4291, a GLP-1/GIP co-agonist prodrug for obesity, support potential for once-monthly dosing; data from 12-week MAD (Part C) on track for Q4 2026 Nomination of development candidate MBX 6180, a GLP-1/GIP/GCG triple agonist prodrug designed for once-monthly dosing, further expands obesity portfolio $418.6 million in cash and investments expected to support operations into 2029 CARMEL, Ind. and BURLINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) — MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for...

Mid-cycle meeting completed for ulixacaltamide HCl; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of January 29, 2027 Mid-cycle meeting completed for relutrigine; FDA identified no major safety or efficacy concerns to date and does not plan to request an advisory committee meeting; PDUFA date of December 27, 2026 FDA Bioresearch Monitoring (BIMO) inspections of Praxis for both ulixacaltamide and relutrigine completed with no Form FDA 483 observations Commercial infrastructure build-out accelerating for ulixacaltamide HCl in Essential Tremor and relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) ahead of expected approvals Praxis received its third Breakthrough Therapy Designation following the positive results from the EMBRAVE...

WILMINGTON, Del., Aug. 06, 2026 (GLOBE NEWSWIRE) — Acorn Energy, Inc. (Nasdaq: ACFN), a provider of remote monitoring and control solutions for generators, gas pipelines, cell tower campuses and other critical infrastructure, announced results for its 2026 second quarter (Q2’26) and six months (6M’26) ended June 30, 2026. Acorn will hold an investor call today at 11am ET (details below). Summary Financial Results (1)($000s except per share data)   Q2’26   Q2’25 Change   6M’26   6M’25 ChangeMonitoring revenue $ 1,425 $ 1,320 +8.0% $ 2,842 $ 2,589 +9.8%Hardware revenue $ 1,064 $ 2,205 -51.7% $ 1,874 $ 4,034 -53.5%Total revenue $ 2,489 $ 3,525 -29.4% $ 4,716 $ 6,623 -28.8%Gross margin   82.4%   74.9% +750 bps   81.3%   75.0% +630 bpsNet income to stockholders $ 294 $ 720 -59.2% $ 217 $ 1,184 -81.7%Net...

PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-term BLA completion for HR BCG-unresponsive NMIBC expected fourth quarter 2026 Phase 3 BOND-003 Cohort C Study Results published in The Lancet Oncology, further validating the strength of the clinical evidence supporting cretostimogene Well-positioned to deliver on key milestones with approximately $1.0 billion cash, cash equivalents and marketable securities sufficient to fund operations through 2029DALLAS, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the second quarter ended June 30, 2026, and provided business updates. “This quarter we have made significant progress across our clinical, regulatory, manufacturing and...